Spain Cancer Immunotherapy Market Size & Outlook
Spain cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Spain cancer immunotherapy market highlights
- The Spain cancer immunotherapy market generated a revenue of USD 3,319.0 million in 2023 and is expected to reach USD 6,410.1 million by 2030.
- The Spain market is expected to grow at a CAGR of 9.9% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 3,319.0 million |
| Market revenue in 2030 | USD 6,410.1 million |
| Growth rate | 9.9% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Spain accounted for 2.6% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 6,410.1 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 65.83% in 2023. Horizon Databook has segmented the Spain cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The program focused on nascent and emerging immunotherapeutic approaches, scientific advancements, ongoing clinical trials, opportunity analysis, methodology to reduce & mitigate adverse effects caused due to cancer treatment, and multidisciplinary approaches for optimal application of immunotherapy for treatment of cancer.
Earlier, Spain had hosted the European Society for Medical Oncology (ESMO) Congress in October2019. The forum discussions threw light on advanced cancer diagnosis, cancer vaccines, cellular therapies, and RNA therapy.
Cancer R&D of new drugs has been rapidly increasing in Spain and we anticipate the country to demonstrate healthy growth over the forecast period. Several players are entering the cancer immunotherapy market in Spain. For instance, Oryzon Genomics is investigating a combination of its epigenetic drug with chemotherapy in lung cancer.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain cancer immunotherapy market size, by product, 2018-2030 (US$M)
Spain Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
